Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

New application of a stabilized active cyclophosphamide derivative (Mafosfamide, ASTA Z 7654) — immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug

Abstract

Lymphatic leukemia L 1210 cells were treated in vitro with various concentrations of Mafosfamide — a stabilized active derivative of cyclophosphamide (4-hydroxycyclophosphamide). L 1210 cells treated with Mafosfamide (L 1210-MAF cells) were used for vaccination of semisyngeneic CD2F1 mice against L 1210 leukemia. These cells do not grow in vivo but are viable in the test with trypan blue. L 1210-MAF cells, obtained by treatment of L 1210 cells two times with 50 μg/ml or 100 μg/ml of Mafosfamide, and injected into the mice induced resistance against L 1210 leukemia in these animals. L 1210 cells treated two times with higher concentration of Mafosfamide (200 μg/ml or 400 μg/ml) did not give this effect.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Alberts DS, Einspahr JG, Struck R, Bignami G, Young L, Surwit EA, Salmon SE: Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Invest New Drugs 2:141–148, 1984

  2. 2.

    Turk JL, Parker D: Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 65:99–113, 1982

  3. 3.

    Diamantatein T, Klos M, Hahn H, Kaufmann SHE: Direct in vitro evidence for different susceptibilities to 4-hydroxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: a possible explanation for the inverse action of cyclophosphamide on humoral and cell-mediated immune responses. J Immunol 126:1717–1719, 1981

  4. 4.

    Douay L, Corin NC, Laporte J-P, Lopez M, Najman A, Duhamel G: ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Invest New Drugs 2:187–190, 1984

  5. 5.

    Kawalec M, Jakóbisiak M, Skórski T, Kawiak J: Immunogenicity of cyclophosphamide-treated leukemia cells. Folia Biol (Praha) 28:334–343, 1982

  6. 6.

    Skórski T, Kawalec M, Hoser G: Cyclophosphamide or ifosfamide treated L 1210 leukemia cells: immunogenicity, viability and metabolism. Folia Biol (Praha) 32:354–365, 1986

  7. 7.

    Lichtfield JT: A method for rapid graphic solution of time-percent effect curves. J Pharmacol Exp Ther 97:399–408, 1949

  8. 8.

    Lichtfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113, 1949

Download references

Author information

Correspondence to Tomasz Skórski.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Skórski, T., Kawalec, M. New application of a stabilized active cyclophosphamide derivative (Mafosfamide, ASTA Z 7654) — immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug. Invest New Drugs 5, 167–169 (1987). https://doi.org/10.1007/BF00203542

Download citation

Key words

  • mafosfamide-treated L 1210 leukemia cells
  • immune resistance
  • CD2F1 mice